O	0	3	p53	p53	NN	B-NP
O	4	12	mutation	mutation	NN	I-NP
O	13	26	heterogeneity	heterogeneity	NN	I-NP
O	27	29	in	in	IN	B-PP
B-Cancer	30	36	cancer	cancer	NN	B-NP
O	36	37	.	.	.	O

O	39	42	The	The	DT	B-NP
O	43	46	p53	p53	NN	I-NP
O	47	51	gene	gene	NN	I-NP
O	52	54	is	be	VBZ	B-VP
O	55	66	inactivated	inactivate	VBN	I-VP
O	67	69	in	in	IN	B-PP
O	70	75	about	about	RB	B-NP
O	76	78	50	50	CD	I-NP
O	78	79	%	%	NN	I-NP
O	80	82	of	of	IN	B-PP
O	83	88	human	human	JJ	B-NP
B-Cancer	89	96	cancers	cancer	NNS	I-NP
O	97	100	and	and	CC	O
O	101	104	the	the	DT	B-NP
O	105	108	p53	p53	NN	I-NP
O	109	116	protein	protein	NN	I-NP
O	117	119	is	be	VBZ	B-VP
O	120	122	an	an	DT	B-NP
O	123	132	essential	essential	JJ	I-NP
O	133	142	component	component	NN	I-NP
O	143	145	of	of	IN	B-PP
O	146	149	the	the	DT	B-NP
B-Cell	150	154	cell	cell	NN	I-NP
O	155	163	response	response	NN	I-NP
O	164	171	induced	induce	VBN	B-VP
O	172	174	by	by	IN	B-PP
O	175	184	genotoxic	genotoxic	JJ	B-NP
O	185	193	stresses	stress	NNS	I-NP
O	194	198	such	such	JJ	B-PP
O	199	201	as	as	IN	I-PP
O	202	207	those	those	DT	B-NP
O	208	217	generated	generate	VBN	B-VP
O	218	220	by	by	IN	B-PP
O	221	233	radiotherapy	radiotherapy	NN	B-NP
O	234	236	or	or	CC	I-NP
O	237	249	chemotherapy	chemotherapy	NN	I-NP
O	249	250	.	.	.	O

O	251	253	It	It	PRP	B-NP
O	254	256	is	be	VBZ	B-VP
O	257	266	therefore	therefore	RB	B-ADVP
O	267	273	highly	highly	RB	B-ADJP
O	274	280	likely	likely	JJ	I-ADJP
O	281	285	that	that	IN	B-SBAR
O	286	291	these	these	DT	B-NP
O	292	303	alterations	alteration	NNS	I-NP
O	304	307	are	be	VBP	B-VP
O	308	310	an	an	DT	B-NP
O	311	320	important	important	JJ	I-NP
O	321	330	component	component	NN	I-NP
O	331	333	in	in	IN	B-PP
B-Cancer	334	339	tumor	tumor	NN	B-NP
O	340	350	resistance	resistance	NN	I-NP
O	351	353	to	to	TO	B-PP
O	354	361	therapy	therapy	NN	B-NP
O	361	362	.	.	.	O

O	363	366	The	The	DT	B-NP
O	367	377	particular	particular	JJ	I-NP
O	378	393	characteristics	characteristic	NNS	I-NP
O	394	396	of	of	IN	B-PP
O	397	402	these	these	DT	B-NP
O	403	414	alterations	alteration	NNS	I-NP
O	414	415	,	,	,	O
O	416	418	80	80	CD	B-NP
O	418	419	%	%	NN	I-NP
O	420	422	of	of	IN	B-PP
O	423	428	which	which	WDT	B-NP
O	429	432	are	be	VBP	B-VP
O	433	441	missense	missense	JJ	B-NP
O	442	451	mutations	mutation	NNS	I-NP
O	452	459	leading	lead	VBG	B-VP
O	460	462	to	to	TO	B-PP
O	463	475	functionally	functionally	RB	B-NP
O	476	489	heterogeneous	heterogeneous	JJ	I-NP
O	490	498	proteins	protein	NNS	I-NP
O	498	499	,	,	,	O
O	500	504	make	make	VB	B-VP
O	505	508	p53	p53	NN	B-NP
O	509	510	a	a	DT	B-NP
O	511	517	unique	unique	JJ	I-NP
O	518	522	gene	gene	NN	I-NP
O	523	525	in	in	IN	B-PP
O	526	529	the	the	DT	B-NP
O	530	535	class	class	NN	I-NP
O	536	538	of	of	IN	B-PP
B-Cancer	539	544	tumor	tumor	NN	B-NP
O	545	555	suppressor	suppressor	NN	I-NP
O	556	561	genes	gene	NNS	I-NP
O	561	562	.	.	.	O

O	563	564	A	A	DT	B-NP
O	565	577	considerable	considerable	JJ	I-NP
O	578	584	number	number	NN	I-NP
O	585	587	of	of	IN	B-PP
O	588	594	mutant	mutant	JJ	B-NP
O	595	598	p53	p53	NN	I-NP
O	599	607	proteins	protein	NNS	I-NP
O	608	616	probably	probably	RB	B-ADVP
O	617	621	have	have	VBP	B-VP
O	622	624	an	an	DT	B-NP
O	625	634	oncogenic	oncogenic	JJ	I-NP
O	635	643	activity	activity	NN	I-NP
O	644	647	per	per	FW	B-ADVP
O	648	650	se	se	FW	I-ADVP
O	651	654	and	and	CC	O
O	655	664	therefore	therefore	RB	B-VP
O	665	673	actively	actively	RB	I-VP
O	674	685	participate	participate	VB	I-VP
O	686	688	in	in	IN	B-PP
B-Cell	689	693	cell	cell	NN	B-NP
O	694	708	transformation	transformation	NN	I-NP
O	708	709	.	.	.	O

O	710	713	The	The	DT	B-NP
O	714	718	fact	fact	NN	I-NP
O	719	723	that	that	IN	B-SBAR
O	724	727	the	the	DT	B-NP
O	728	737	apoptotic	apoptotic	JJ	I-NP
O	738	741	and	and	CC	I-NP
O	742	759	antiproliferative	antiproliferative	JJ	I-NP
O	760	769	functions	function	NNS	I-NP
O	770	772	of	of	IN	B-PP
O	773	776	p53	p53	NN	B-NP
O	777	780	can	can	MD	B-VP
O	781	783	be	be	VB	I-VP
O	784	795	dissociated	dissociate	VBN	I-VP
O	796	798	in	in	IN	B-PP
O	799	806	certain	certain	JJ	B-NP
O	807	814	mutants	mutant	NNS	I-NP
O	815	819	also	also	RB	B-ADVP
O	820	828	suggests	suggest	VBZ	B-VP
O	829	836	another	another	DT	B-NP
O	837	842	level	level	NN	I-NP
O	843	845	of	of	IN	B-PP
O	846	856	complexity	complexity	NN	B-NP
O	857	859	in	in	IN	B-PP
O	860	863	the	the	DT	B-NP
O	864	877	relationships	relationship	NNS	I-NP
O	878	885	between	between	IN	B-PP
O	886	889	p53	p53	NN	B-NP
O	890	902	inactivation	inactivation	NN	I-NP
O	903	906	and	and	CC	I-NP
B-Cancer	907	916	neoplasia	neoplasia	NN	I-NP
O	916	917	.	.	.	O

